Heptares Achieves All Research Milestones and Receives Milestone Payment From GPCR Drug Discovery Agreement With Takeda Pharmaceutical Co. Ltd. (TKPYY)
4/29/2013 8:28:30 AM
More...
|
Heptares to Present at Upcoming Scientific and Biotech Industry Conferences
4/16/2013 6:41:00 AM
More...
|
Heptares to Present at Boston Biotech BD and Future Leaders in the Biotech Industry Conferences
4/3/2013 6:17:31 AM
More...
|
Heptares Stars® Enable "Reverse Pharmacology" Approach to Accelerate GPCR-Focused Drug Discovery
3/18/2013 9:57:05 AM
More...
|
MorphoSys AG and Heptares Sign Alliance to Develop Antibody Therapeutics Targeting GPCRs
2/13/2013 10:11:51 AM
More...
|
Heptares and UK Medical Research Council (MRC) Extend GPCR Collaboration
6/19/2012 12:00:40 PM
More...
|
Heptares Review Article Highlights Promise of Structure-Based Drug Design for G Protein Coupled Receptors (GPCRs)
4/25/2012 10:13:16 AM
More...
|
Heptares Grants Shire plc an Exclusive Worldwide $190 Million License to Develop and Commercialise Novel Drug Candidate for CNS Disorders
3/20/2012 6:48:48 AM
More...
|
Heptares to Present at 6th Annual BIO-Europe Spring Conference on 20 March 2012
3/15/2012 10:42:24 AM
More...
|
Oxygen Healthcare Ltd. (O2h) Announces Expanded Chemistry Collaboration With Heptares
7/14/2011 6:02:35 AM
More...
|
|